HLA-G and MIC expression in tumors and their role in anti-tumor immunity

Trends in Immunology

Volumn 24, Issue 2, 2003, Pages 82-87

  Seliger, Barbara ^a   Abken, Hinrich ^b   Ferrone, Soldano ^c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANTIGEN RECOGNITION; BIOAVAILABILITY; HISTOLOGY; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; MAJOR HISTOCOMPATIBILITY COMPLEX; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR RECOGNITION; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 0037301791     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(02)00039-X     Document Type: Article

References (46)

1. Smyth M.J., et al. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2:2001;293-299.
2. O'Callaghan C.A., Bellm J.I. Structure and function of the human MHC class Ib molecules HLA-E, HLA-F and HLA-G. Immunol. Rev. 163:1998;129-138.
3. Bahram S. MIC genes: from genetics to biology. Adv. Immunol. 76:2000;1-60.
4. Carosella E.D., et al. HLA-G and HLA-E: fundamental and pathophysiological aspects. Immunol. Today. 21:2000;532-534.
5. Park B., et al. The truncated cytoplasmic tail of HLA-G serves a quality-control function in post-ER compartments. Immunity. 15:2001;213-224.
6. Paul P., et al. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6 and -G7 transcripts in human transfected cells. Hum. Immunol. 61:2000;1138-1149.
7. Bainbridge D., et al. HLA-G remains a mystery. Trends Immunol. 22:2001;548-552.
8. Amiot L., et al. Distribution of HLA-G alternative mRNAs including soluble forms in normal lymphocytes and in lymphoid-cell-derived leukemia. Eur. J. Immunogenet. 23:1996;311-320.
9. Gobin S.J., van den Elsen P.J. Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F and HLA-G. Hum. Immunol. 61:2000;1102-1107.
10. Lefebvre S., et al. A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this non-classical class I gene by IFN-β J. Biol. Chem. 276:2001;6133-6139.
11. Urosevic M., et al. Human leukocyte antigen G upregulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am. J. Pathol. 159:2001;817-824.
12. Ibrahim E.C., et al. Heat shock and arsenite induce expression of the non-classical class I histocompatibility HLA-G gene in tumor-cell lines. Cell Stress Chaperones. 5:2000;207-218.
13. Davies B., et al. HLA-G expression by tumors. Am. J. Reprod. Immunol. 45:2001;103-107.
14. Polakova K., Russ G. Expression of the non-classical HLA-G antigen in tumor-cell lines is extremely restricted. Neoplasm. 47:2000;342-348.
15. Paul P., et al. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res. 59:1999;1954-1960.
16. Paul P., et al. HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. Hum. Immunol. 61:2000;1177-1195.
17. Ugurel S., et al. HLA-G in melanoma: A new strategy to escape from immunosurveillance? Onkologie. 25:2002;129-134.
18. Mizuno S., et al. Aberrant expression of HLA-G antigen in interferon-γ-stimulated acute myelogenous leukaemia. Br. J. Haematol. 111:2000;280-282.
19. Paul P., et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc. Natl. Acad. Sci. U. S. A. 95:1998;4510-4515.
20. Wagner S.N., et al. Expression analysis of classic and non-classic HLA molecules before interferon-α-2b treatment of melanoma. Lancet. 356:2000;220-221.
21. Hurks H.M., et al. Uveal melanoma: no expression of HKLA-G. Invest. Opthalmol. Vis. Sci. 42:2001;3081-3084.
22. Wiendl H., et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J. Immunol. 168:2002;4772-4780.
23. Ibrahim E.C., et al. Tumor-specific upregulation of the non-classical class I HLA-G antigen expression in renal carcinoma. Cancer Res. 61:2001;6838-6845.
24. Willers J., et al. Decreased intra-individual HLA class I expression is due to reduced transcription in advanced melanoma and does not correlate with HLA-G expression. J. Invest. Dermatol. 117:2001;1498-1504.
25. Cabestre F., et al. HLA-G expression in human melanoma cells: protection from NK cytolysis. J. Reprod. Immunol. 43:1999;183-193.
26. Marchal-Bras-Goncalves R., et al. A soluble HLA-G protein that inhibits natural killer-cell-mediated cytotoxicity. Transplant. Proc. 33:2001;2355-2359.
27. Llano M., et al. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur. J. Immunol. 28:1998;2854-2863.
28. + cells by interacting with CD8. J. Immunol. 164:2000;6100-6104.
29. + cells and inhibit cytotoxic T-cell activity through CD8 ligation. Eur. J. Immunol. (in press).
30. Dorling A., et al. HLA-G inhibits the transendothelial cell migration of human NK cells: a strategy for inhibiting xenograft rejection. Transplant. Proc. 32:2000;938.
31. Carosella E.D., et al. HLA-G: a shield against inflammatory aggression. Trends Immunol. 22:2001;553-555.
32. Lepin E.J., et al. Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur. J. Immunol. 30:2000;3552-3561.
33. Collins R.R., et al. High resolution molecular phenotiying of MICA and MICB alleles using sequence specific primers. Hum. Immunol. 63:2002;783-794.
34. Stephens H.A. MICA and MICB genes: can the enigma of their polymorphism be resolved? Trends Immunol. 22:2001;378-385.
35. Pende D., et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor-cell lines of different histotypes: Analysis of tumor susceptibility to NKG2D-dependent natural killer-cell cytotoxicity. Cancer Res. 62:2002;6178-6186.
36. Groh V., et al. Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB. Proc. Natl. Acad. Sci. U. S. A. 96:1999;6879-6884.
37. Vetter C.S., et al. Expression of stress-induced MHC class I related chain molecules on human melanoma. J. Invest. Dermatol. 118:2002;600-605.
38. Ghaderi M., et al. Tumor necrosis factor α-11 and DR15-DQ6 (B*0602) haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women in northern Sweden. Cancer Epidemiol. Biomarkers Prev. 9:2000;1067-1070.
39. Kennedy C., et al. MICA gene polymorphism is not associated with an increased risk for skin cancer. J. Invest. Dermatol. 118:2002;686-691.
40. Menier C., et al. MICA triggering signals for NK-cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal. Int. J. Cancer. 100:2002;63-70.
41. Groh V., et al. Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat. Immunol. 2:2001;255-260.
42. Groh V., et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 419:2002;734-738.
43. Ugurel S., et al. Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-α immunotherapy. Cancer. 92:2001;369-376.
44. Kuppen P.J., et al. Role of NK in adoptive immunotherapy of metastatic colorectal cancer in a syngeneic rat model. Immunol. Rev. 184:2001;236-243.
45. Lefebvre S., et al. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J. Pathol. 196:2002;266-274.
46. Urosevic M., et al. HLA-G protein upregulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood. 99:2002;609-617.